Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey.

"Conflict of interest Hiroshi Nakase reports receiving personal fees from AbbVie GK, Daiichi Sankyo, EA Pharma, Janssen, JIMRO, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer Inc., Takeda, and Gilead Sciences Inc., research grants from HOYA Pentax Medical, Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, and Mochida Pharmaceutical Co., Ltd., and scholarship grants from AbbVie GK, EA Pharma, Mitsubishi Tanabe Pharma Corporation, and Nippon Kayaku. Takayuki Matsumoto reports receiving personal fees from Janssen, Tanabe-Mitsubishi Pharmaceutical, EA Pharma, and Takeda Pharmaceutical and scholarship grants from Nippon Kayaku and Tanabe-Mitsubishi Pharmaceutical. Minoru Matsuura reports receiving personal fees from Janssen Pharmaceutical K.K. and Takeda Pharmaceutical Co., Ltd. Katsuyoshi Matsuoka reports receiving personal fees from Mitsubishi Tanabe Pharma, AbbVie, Takeda Pharmaceutical, EA Pharma, Janssen Pharmaceutical, and Pfizer, research grants from Janssen Pharmaceutical, and scholarship grants from Mitsubishi Tanabe Pharma, AbbVie, EA Pharma, and Mochida Pharmaceutical. Shunji Ishihara reports receiving personal fees from Takeda Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation, and research grants from Janssen Pharmaceutical K.K. Fumihito Hirai reports receiving personal fees from AbbVie GK, EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., and Takeda Pharmaceutical Co., Ltd., research grants from Eli Lily Japan K.K., Janssen Pharmaceutical K.K., and AbbVie GK., and scholarship grants from AbbVie GK, EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Co. Ken Takeuchi reports receiving personal fees from Mochida, AbbVie, Janssen pharma, Pfizer, and EA Pharma, and research grants from AbbVie, Takeda, Eli Lilly, Celgene, Shin Nippon Biomedical Laboratories, EA Pharma, Astra Zeneca, and Janssen pharma. Makoto Naganuma reports receiving personal fees from Takeda Pharmaceutical Co., Ltd., AbbVie GK, Mitsubishi Tanabe Pharma Corp, and Pfizer Co., Ltd., research grants from Mochida Pharmaceutical Co., Ltd., and scholarship grants from Takeda Pharmaceutical Co., Ltd., AbbVie GK, Mitsubishi Tanabe Pharma Corp, and Pfizer Co., Ltd. Kenji Watanabe reports receiving personal fees from, AbbVie Japan Co., Ltd., EA Pharma Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Kissei Pharmaceutical Co., Ltd., research grants from EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and EP‐CRSU Co., Ltd., scholarship grants from AbbVie Japan Co., Ltd., EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, JIMRO Co., Ltd., and Nippon Kayaku Co., Ltd., and endowed chair from AbbVie Japan Co., Ltd., EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, ZERIA Pharmaceutical Co. Ltd., JIMRO Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Asahi Kasei Medical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Satoshi Motoya reports receiving personal fees from AbbVie GK, Mitsubishi-Tanabe Pharma Corporation, Takeda Pharmaceutical Corporation, and Janssen Pharmaceutical KK., and scholarship grants from AbbVie GK and Janssen Pharmaceutical KK. Atsuo Maemoto reports receiving research grants from Gilead Sciences, Inc., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Takeda Pharmaceutica Company, and Pfizer R&D Japan G.K. Hirotake Sakuraba reports receiving research grants from LAVIEPRE Co., Ltd., Yakult Honsha Co., Ltd., and Bristol-Myers Squibb Company, and scholarship grants from Eisai Co., Ltd. and Aomori Ai Co. Masayuki Saruta reports receiving personal fees from AbbVie GK, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Gilead Sciences K.K., research grants from EPS Corporation, and scholarship grants from Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Kissei Pharmaceutical Co., Ltd. Hiroki Tanaka reports receiving personal fees from JIMRO Co., Ltd., AbbVie GK, EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Nikkiso Co., Ltd., and Takeda Pharmaceutical, and research grants from AbbVie GK, Janssen Pharmaceutical K.K., EA Pharma, and Takeda Pharmaceutical. Sakiko Hiraoka reports receiving personal fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, and Takeda Pharmaceutical Co., Ltd. Tadakazu Hisamatsu reports receiving personal fees from EA pharma Co., Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Mochida Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., research grants from Alfresa Pharma Co., Ltd. and EA pharma Co., Ltd., and scholarship grants from Mitsubishi Tanabe Pharma Corporation, EA pharma Co., Ltd., AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd."

"Funding This work was supported by the Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare (MHLW) of Japan (Investigation and Research for intractable Inflammatory Bowel Disease) (Grant Number 20FC1037), and by MHLW Research Program on Emerging and Reemerging Infections Diseases (Grant Number JPMH21HA2011)."

"First, the co-authors developed the questionnaire by referring to previous reports [, ] and adding questions that they thought would be useful for gathering information regarding anxiety of IBD patients. After that, Japan IBD COVID-19 task force members (HN, TM, MM, HI, KM, NO, SI, FH, and TH) conducted internal evaluations several times to complete the questionnaire. The questionnaire consisted of six major domains, some of which were rated on a ten-point visual analog scale (VAS) and focused on the impact of COVID-19 on anxiety related to IBD, disease activity, medical examination, IBD medication, and prevention of infection (Questionnaire in the Supplementary Material). The reason for using the VAS in this study was to ensure that patients could show their feelings easily and the difference could be measured. Additionally, we collected and assessed data regarding demographics, socioeconomic status, IBD diagnoses, comorbidities, and current IBD treatment. The primary outcome was the VAS score for disease-related anxiety during the pandemic [Q1. (1) How much anxiety did you feel about your disease due to the outbreak of SARS-CoV-2?]. This study protocol was approved by the institutional review board of Sapporo Medical University and registered publicly on the UMIN registration (No. UMIN000041191)."